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Severe asthma is a subset of difficult-to-treat asthma; it is characterized by uncontrolled 
respiratory symptoms despite both adherence 
to maximal optimized therapy and treatment of 
comorbidities and risk factors, or worsening of 
symptoms when maximal therapy is decreased.1-9 
The prevalence of severe asthma stands around 
3.7%, calculated on the basis of step 4 or 5 ongo-
ing treatment (according to the stepwise thera-
peutic approach provided by Global initiative for 
asthma [Gina], recommendations), symptom 
control and adherence evaluations. about 3-10% 
of patients with asthma are estimated to present 
severe asthma.10
Clinicians defined several phenotypes based 
on clinical presentation, onset age, disease se-
verity, presence of allergic sensitization and 
eosinophilia. The diagnosis of severe asthma 
is based on the review of some clinical comor-
bidities (such as gastroesophageal reflux, chron-
ic obstructive pulmonary disease, anxiety and 
depression, chronic rhinosinusitis, obstructive 
sleep apnea syndrome, bronchiectasis, cardiac 
failure, obesity, inducible laryngeal obstruction, 
and kyphosis) and risk factors (such as: tobacco 
smoking; environmental exposure to air pollut-
ants, allergens, noxious chemicals, and molds; 
beta-blockers or non-steroid anti-inflammatory 
drugs therapies) that could hide a difficult-to-
treat-asthma, in order to assess clinical pheno-
types.10 This approach is driven by precision 
medicine, a new medical model which tailors 
the management on individual genetic, genomic, 
environmental, psychosocial characteristics, but 
also personal preferences.11
Many studies identified and validated differ-
ent phenotypes of severe asthma based not only 
on onset age and eventual comorbidities, but 
also on underlying immunological mechanisms, 
identifying the so called “endophenotypes” that 
are more closely related to the biological pro-
cesses of the disease.12 notably, both type 2 and 
non-type 2 inflammation play important role in 
underlying immune responses of severe asthma 
pathophysiology. In particular, type 2 inflamma-
tion is characterized by the presence of eosino-
philia in airways, associated with increased T 
helper type 2 (Th2) cytokines release from Th2 
cells.13 On the contrary, non-type 2 neutrophilic 
underlying mechanisms are less characterized, 
involving a dysregulated release of pro-resolving 
lipid mediators and a reduced number of natural 
killer cells.14
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halving of severe exacerbations frequency, with 
improvement of the QoL, symptoms control and 
lung function and a 50% reduction of the OcS 
doses versus placebo.10
very recently, akenroye et al. suggested a role 
of these biologic agents in viral exacerbated dis-
ease. it is likely that these biologics would reduce 
the risk of severe asthma exacerbations cOv-
id-19 mediated, at least by reducing baseline air-
way inflammation, and possibly through specific 
antiviral properties. Omalizumab, cross-linking 
ige, would lead to lower type 1 interferon (inF) 
production; mepolizumab, reslizumab and ben-
ralizumab, act by increasing the ratio of IFN-γ-to-
iL-5 mrna, which is associated with lower viral 
shedding and faster disease clearance. Finally, 
iL-4 is crucial for antibody switching to ige, and 
iL-13 is a Th2 cytokine involved in airway hyper 
responsiveness and remodeling; both of them are 
involved in susceptibility and in clearance of viral 
infections affecting lower airways.16
Severe acute respiratory Syndrome corona-
virus -2 (SARS-CoV-2) was recently identified 
first in Wuhan (China), and defined as responsi-
ble of clinical manifestations named coronavirus 
disease 2019 (cOvid-19).17-20 current guidance 
from the World Health Organization (WHO) 
highlights asthmatics as a high-risk group for se-
vere illness from SarS-cov-2. So far this sus-
pect has not been confirmed by the most recently 
published studies: in fact, while asiatic reports 
identified a low prevalence of asthma in patients 
affected by SarS-cov-2,21 in the USa the es-
timated prevalence was near to 20% in patients 
with laboratory-confirmed diagnosis of COV-
id-19.22 in italy, preliminary data seem to be in 
line with the asian studies results: the frequency 
of asthmatic patients in cOvid departments is 
estimated to be around 2-3% versus 6% in the 
general population (unpublished data). allergic 
asthmatic subjects seem to be less likely infected 
by the SarS-cov-2 and this could be due to dif-
ferent factors. The first hypothesis might be re-
lated to the anti-inflammatory effect exerted by 
the inhaled corticosteroids and their negative ef-
fect on the cytokine storm elicited by the virus. 
Furthermore, compliance to antiasthmatic treat-
ment could be increased, due to fear that the viral 
infection could impair the clinical course.
phoid cells, may be triggered by both allergens, 
leading to interleukin (iL)-4, iL-5 and iL-13 re-
lease, and other external stimuli (virus, bacteria, 
irritants), through the production of iL-25, iL-33 
and thymic stromal lymphopoietin (TSLP) by 
epithelial cells; both the pathways induce type 
2 inflammation, characterized by eosinophilia 
or increased fraction of exhaled nO (FenO). in 
severe asthma, type 2 inflammation may present 
a relatively refractory response to high dose of 
inhaled corticosteroids (icS), but responding to 
oral corticosteroids (OcS), nevertheless expos-
ing the patient to serious adverse effects.10
recent progresses in severe asthma treatment 
focused on target therapy, with the introduction 
of biological therapies as add-on treatment to 
step 5 of Gina recommendations. These biolog-
ical drugs target specific cytokines involved in 
the pathophysiology of severe asthma, opening 
the way to precision medicine.11
different biological agents have been recent-
ly approved for the treatment of type 2 severe 
asthma. Omalizumab is a recombinant human-
ized monoclonal anti-ige antibody for allergic 
asthma; it binds to circulating ige, preventing 
it from binding with both high- and low-affinity 
receptors on effector cells (mast cells and baso-
phils), and leading to a reduction in the release 
of allergic mediators. nowadays, there are sev-
eral scientific evidences about omalizumab clini-
cal effects, including a statistical reduction of 
asthma exacerbations, reduction of OcS dosage, 
and significant improvement of the quality of life 
(QoL).10 Mepolizumab and reslizumab are both 
humanized recombinant monoclonal anti-iL-5 
antibodies that bind to circulating iL-5, where-
as benralizumab is a recombinant monoclonal 
anti-iL-5 receptor (r) alpha subunit antibody, 
leading to apoptosis of eosinophils; anti-iL-5 
and anti-iL-5r reduce about 50% of severe ex-
acerbations, improve QoL, lung function and 
symptoms control. even OcS dose is reduced 
by 50% in patients in treatment with benrali-
zumab and mepolizumab, when compared with 
placebo.10 Finally, dupilumab is a recombinant 
human monoclonal anti-iL-4r alpha antibody, 
blocking iL-4 and iL-13 signaling;15 in severe 
asthma patients with at least one exacerbation in 
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going treatment, preferably at home with the ini-
tiation of a self-administration after a maximum 
of 2 in-hospital visits. in europe, omalizumab is 
now approved for home-administration after the 
first administration in clinic; for the other biolog-
ics, the switch to prefilled syringes encourages 
the at home self-administration, but only after 
an adequate training to recognize early signs and 
symptoms of serious adverse reactions.27
in conclusion, further studies are needed to 
define interactions between SARS-CoV-2 and 
asthma; up to now, the risk of severe cOvid-19 
may not be dramatically increased in asthmatic 
patients but the incidence may be variable world-
wide due to the different methodology of pub-
lished studies, since the latter are still inconclu-
sive ad inhomogeneous. The recommendable tar-
get however is to maintain asthma under control 
and limit the occurrence of asthma symptoms 
and severe exacerbations with the minimum ef-
fective dosage of steroids and the ongoing bio-
logical treatments.
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